Figure S3.

A.

#1. No IFN
#2. Pretreated 10UI/ml IFN-β
#3. Pretreated 100UI/ml IFN-β
#4. Post-treated 100UI/ml IFN-β

B.

Cells with SG (%)

<table>
<thead>
<tr>
<th>#1</th>
<th>#2</th>
<th>#3</th>
<th>#4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C.

Infected cells (%)

<table>
<thead>
<tr>
<th>#1</th>
<th>#2</th>
<th>#3</th>
<th>#4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D.

-IFN 100UI/ml
+IFN-β untreated
+arsenite untreated
+DENV-2 +poly I:C

TIAR CAPRIN1